BCG is a nonspecific immunotherapeutic, and combining it with an “immune checkpoint” inhibitor may give effective results even in BCG monotherapy-unresponsive tumors, especially if PD-L1 is present in tumor cells [53]. This evidence concerns the gene CD274 and neoplasm.